As WTO Member States continue to discuss an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics, latest evidence and data published today explains what the consequences of such a waiver would have on industry’s ability to fight the COVID-19 pandemic.

Any waiver will also have a significant adverse impact on the entire innovation ecosystem, that in turn will negatively affect industry’s ability to address future pandemics.